HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG ), a clinical-stage biotechnology company with 160+ patents issued and pending focused on developing therapies and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application covering methods of treating splenomegaly using a cell-based therapeutic approach.

Splenomegaly, or an enlarged spleen, often occurs in association with immune-related conditions and is seen in a variety of diseases, including autoimmune diseases and chronic infections. In addition, it can also be caused by multiple rounds of chemotherapy and anti-depressant drugs. The spleen is important for filtering blood, supporting the immune system and managing red blood cells. But in cases of immune diseases, it can become overactive, leading to enlargement. Conditions such as psoriasis, lupus, HIV, tuberculosis and blood cancers such as lymphoma and leukemia are common causes of this problem. When the spleen becomes enlarged to deal with excess immune cells and inflammation, it can lead to discomfort, anemia and a weakened immune system, increasing vulnerability to further infections.

“This patent application highlights the potential of fibroblast-based therapies to address immune-related disorders, such as splenomegaly,” said Pete O’Heeron, Founder and CEO of FibroBiologics. dysregulation, underscoring their promise in treating complex conditions linked to immune system dysfunction.”

“Filing this patent application is an important milestone in the development of fibroblast-based therapies for immune-driven diseases,” added Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. “Unlike traditional treatments, fibroblasts may offer a potential solution in line with the host’s biological processes to help regulate immune activity in the spleen, opening new possibilities for managing conditions involving immune system overload and splenic stasis.”

For more information, visit FibroBiologics’ website or email FibroBiologics at: (email protected).

Cautionary Notice Regarding Forward-Looking Statements

This announcement contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information about the potential of fibroblast-based therapies to address immune-related disorders, such as splenomegaly, and to open new opportunities for managing conditions involving the overload of the immune system and splenomegaly, and the promise of fibroblast-based therapies in the treatment of complex conditions linked to immune system dysfunction. These forward-looking statements are based on FibroBiologic’s management’s current expectations, estimates, projections and beliefs, as well as a number of assumptions about future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of FibroBiologic’s management, which could cause actual results to differ materially from those discussed in the forward-looking statements, including those set forth under the heading “Risk Factors” and elsewhere in FibroBiologic’s annual, quarterly and current reports (ie Form 10-K, Form 10-Q and Form 8-K) filed or filed with the SEC and any subsequent public filings. Copies are available on the SEC’s website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologic’s liquidity and its ability to maintain sufficient capital resources to operate its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) The unpredictable relationship between R&D and preclinical results and clinical study results. and (d) FibroBiologic’s ability to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to place undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. FibroBiologics makes no guarantee that they will achieve their expectations.

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds more than 160 US and internationally issued patents/patents in various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution and cancer. FibroBiologics represents the next generation of medical advances in cell therapy. For more information, visit www.FibroBiologics.com.

General questions:

(email protected)

Investor Relations:

Nic Johnson

Russo Partners

(212) 845-4242

(email protected)

Media contact:

Liz Phillips

Russo Partners

(347) 956-7697

(email protected)